NYSE$NUVB

Nuvation Bio Inc · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

NUVB reported Q4 2025, revenue of $41.9M, a net loss of $36.6M, diluted EPS of $-0.11.

For Q4 2025, NUVB reported revenue of $41.9M, a net loss of $36.6M, diluted EPS was $-0.11. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.

  • Revenue $41.9M.
  • Net loss $36.6M.
  • Diluted EPS $-0.11.

Headline financials

Total Revenue

$41.9M

Previous: $5.71M+633.1%
EPS (adj)

-$0.11

Previous: -$0.15+26.7%
R&D Expenses

$34.3M

Previous: $29.3M+17.1%
SG&A Expenses

$40.3M

Previous: $26.1M+54.3%
Marketable Securities

$365M

No prior period
Total Current Assets

$572M

No prior period
Total Liabilities

$289M

No prior period
New Patient Starts

216

No prior period
Net Income

-$36.6M

Previous: -$49.4M+25.9%
Operating Income

-$34M

Previous: -$53.9M+36.9%
Gross Profit

$40.6M

Previous: $1.5M+2614.8%

Revenue & EPS history

Nuvation Bio · Revenue · Quarterly

$41.9M

Q4 2025+633.1%vs Q4 2024
Beat estimate in 4 of 4 quarters(100%)
ActualEstimate

Forward guidance

The quarterly filing discusses operating priorities, capital returns, and sector risks.

Tailwinds

  • MD&A highlights liquidity and core business trends.
  • Segment commentary supports the earnings narrative.

Headwinds

  • Macro or input-cost pressure may affect margins.
  • One-time items can affect YoY comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

+1.1%

Avg return

Earnings day

+2.7%

Avg return

5 days after

+9.3%

Avg return

30 days after

60%

12 / 20 earnings

Positive

+16.4%

Q3 2023

Best reaction

-25.2%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%+6.7%+4.9%
Q4 2025-25.2%-21.4%-24.5%
Q3 2025-6.2%-8.5%+60.7%
Q1 2025+3.5%+7.4%+21.6%
Q4 2024+1.0%+0.0%+0.5%
Q3 2024+12.9%+29.7%+22.8%
Q2 2024-11.3%-15.8%-10.4%
Q1 2024-2.1%-1.5%-11.3%
Q4 2023+13.2%+10.7%+84.8%
Q3 2023+16.4%+15.5%+14.7%
Q2 2023+0.5%+12.0%-10.4%
Q1 2023+4.4%+0.6%+6.9%
Q4 2022+1.2%+0.6%+8.4%
Q3 2022-3.7%-7.4%-7.8%
Q2 2022+7.8%+12.1%+26.8%
Q1 2022-1.8%-9.3%-18.4%
Q4 2021-8.3%-13.7%+0.8%
Q3 2021+3.6%+6.2%+4.0%
Q2 2021+8.6%+4.3%+11.1%
Q1 2021+8.9%+26.7%-0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro